2029, FDA, Sales and Side effects

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2029

FDA

Sales

Side effects

NICE recommends AbbVie’s/J&J’s Imbruvica for combo use in untreated CLL

Pharmaceutical Technology

APRIL 24, 2023

The combination therapy also caused fewer side effects, with heart problems and hypertension as the most common ones, based on the final draft guidance. Brukinsa was approved by the US Food and Drug Administration (FDA) in CLL in January 2023. billion in 2029, while Calquence is expected to make $5.31 billion in 2029.

Food and Drug Administration

Food and Drug Administration Side effects Sales Food

Key Developments from AMCP 2023 on Blockbuster Generics, Diabetes Drugs, PBM Legislation, and More

PM360

SEPTEMBER 21, 2023

Generic Drug Launches This year could see up to 50 generic drug approvals on brand pharmaceuticals worth more than $20 billion in sales, Casberg noted. billion in sales. The product had sales of roughly $800 million per year. The drug generated $2 billion in sales last year. “We’re

Management

Management Manufacturing Sales Competition

Pharma Rep Focus

NICE recommends AbbVie’s/J&J’s Imbruvica for combo use in untreated CLL

Key Developments from AMCP 2023 on Blockbuster Generics, Diabetes Drugs, PBM Legislation, and More

Stay Connected